{"title":"复发性和转移性头颈部鳞状细胞癌因免疫相关不良事件而停止治疗后的预后。","authors":"Hiromasa Ishihara, Yuki Asahi, Masashi Kuroki, Ken Saijo, Ryo Kawaura, Rina Kato, Manato Matsubara, Saki Akita, Tatsuhiko Yamada, Ryota Iinuma, Hiroshi Okuda, Hirofumi Shibata, Takenori Ogawa","doi":"10.1002/hed.70043","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The prognostic impact of immune-related adverse events (irAEs) in recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC) remains unclear, particularly after treatment discontinuation.</p><p><strong>Methods: </strong>This retrospective study included RM-HNSCC patients treated with nivolumab or pembrolizumab. The association between irAEs, treatment response, and prognosis was analyzed. To minimize immortal time bias, survival was assessed at multiple time points. Outcomes after permanent discontinuation due to irAEs were also evaluated.</p><p><strong>Results: </strong>Among 92 cases, 25 cases (27.2%) experienced irAEs. Cases that experienced irAEs showed better progression-free survival than those who did not experience irAEs. Eight cases permanently discontinued treatment due to irAEs, and six cases maintained tumor shrinkage after discontinuing ICI.</p><p><strong>Conclusions: </strong>In this study, irAEs were associated with a good prognosis. Furthermore, it was revealed that many of the cases in which treatment was permanently discontinued due to irAEs continued a durable response even after treatment ended.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prognosis After Discontinued Treatment due to Immune-Related Adverse Events in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma.\",\"authors\":\"Hiromasa Ishihara, Yuki Asahi, Masashi Kuroki, Ken Saijo, Ryo Kawaura, Rina Kato, Manato Matsubara, Saki Akita, Tatsuhiko Yamada, Ryota Iinuma, Hiroshi Okuda, Hirofumi Shibata, Takenori Ogawa\",\"doi\":\"10.1002/hed.70043\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The prognostic impact of immune-related adverse events (irAEs) in recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC) remains unclear, particularly after treatment discontinuation.</p><p><strong>Methods: </strong>This retrospective study included RM-HNSCC patients treated with nivolumab or pembrolizumab. The association between irAEs, treatment response, and prognosis was analyzed. To minimize immortal time bias, survival was assessed at multiple time points. Outcomes after permanent discontinuation due to irAEs were also evaluated.</p><p><strong>Results: </strong>Among 92 cases, 25 cases (27.2%) experienced irAEs. Cases that experienced irAEs showed better progression-free survival than those who did not experience irAEs. Eight cases permanently discontinued treatment due to irAEs, and six cases maintained tumor shrinkage after discontinuing ICI.</p><p><strong>Conclusions: </strong>In this study, irAEs were associated with a good prognosis. Furthermore, it was revealed that many of the cases in which treatment was permanently discontinued due to irAEs continued a durable response even after treatment ended.</p>\",\"PeriodicalId\":55072,\"journal\":{\"name\":\"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/hed.70043\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OTORHINOLARYNGOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/hed.70043","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
Prognosis After Discontinued Treatment due to Immune-Related Adverse Events in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma.
Background: The prognostic impact of immune-related adverse events (irAEs) in recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC) remains unclear, particularly after treatment discontinuation.
Methods: This retrospective study included RM-HNSCC patients treated with nivolumab or pembrolizumab. The association between irAEs, treatment response, and prognosis was analyzed. To minimize immortal time bias, survival was assessed at multiple time points. Outcomes after permanent discontinuation due to irAEs were also evaluated.
Results: Among 92 cases, 25 cases (27.2%) experienced irAEs. Cases that experienced irAEs showed better progression-free survival than those who did not experience irAEs. Eight cases permanently discontinued treatment due to irAEs, and six cases maintained tumor shrinkage after discontinuing ICI.
Conclusions: In this study, irAEs were associated with a good prognosis. Furthermore, it was revealed that many of the cases in which treatment was permanently discontinued due to irAEs continued a durable response even after treatment ended.
期刊介绍：
Head & Neck is an international multidisciplinary publication of original contributions concerning the diagnosis and management of diseases of the head and neck. This area involves the overlapping interests and expertise of several surgical and medical specialties, including general surgery, neurosurgery, otolaryngology, plastic surgery, oral surgery, dermatology, ophthalmology, pathology, radiotherapy, medical oncology, and the corresponding basic sciences.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
